Built for leaders proving demand, not just seeking approval.
A quick check before you book a conversation: the Studio works because every leader in the room is genuinely at the same stage.
Value in MedTech is expanding beyond the device.
Software, AI, data and connected technologies are embedding themselves in products and clinical workflows. Care is moving beyond traditional clinical settings. New commercial models are emerging. For a CEO with a product already earning traction in the market, through full approval, CE marking, or evidenced sales ahead of it, the question is no longer just how to scale it: it's where the business plays next.
Embedding into diagnosis, decision-making and workflow, changing what the product is and who else can build one.
Diagnosis and monitoring moving into primary care and the home, opening a path from single component to whole pathway.
Software, subscription and service revenue building value around the device, not replacing it.
Four connected lenses, applied to what your business becomes next.
A methodology overlay is what makes this systemic rather than simply social. Every leader examines their own version of the question through the same four lenses: a holistic view of the organisation, not a single fix.
The assumptions quietly shaping whether growth means a better device, or a different business.
Whether the team that got you to approval is the team that gets you to scale.
What the business and its people collectively believe growth beyond the device should look like.
The commercial, regulatory and organisational structures that shape what you can actually do next.
One cohort converges on a theme. Each leader brings their own version of the question.
Every participant's underlying strategic question is different: a platform choice, a market entry, a leadership gap. What the cohort shares is why this specific group is in the room together, which is why the journey runs on two tracks.
Where the cohort comes together to work “beyond the device” at the group level, sharing, challenging and supporting each other through structured hot seats and facilitated discussion.
Where each leader works the same question inside their own organisation, supported by digital tools, coaching calls and a rolling plan folded back into the next Studio session.
One journey, using Xenergie's systemic transformation method.
Two sessions stay deliberately peer-only, protecting trust-building and the group's own working time; the other four bring in outside stimulus because the theme asks for it.
Join your peer network to explore what it means to scale beyond just creating devices or technology solutions. Share experiences and get access to the frameworks that show where your organisation's thinking is still built for R&D, not for the market you're now competing in.
Outcomes: new relationships and new leadership frameworks to help you step up in your scaling journey.
Name the tension you're carrying: keeping the business running today while building the leadership and culture your growth actually needs. Work through what's really holding your organisation back.
Outcomes: a clear-eyed view of what has to change in your organisation to support the growth you're chasing.
Bring a decision you're actually facing (a hire, a pivot, an investor conversation) and get it pressure-tested by peers who've been there. Held face-to-face, because this kind of challenge only works in a room.
Outcomes: peer-tested clarity on a decision you have to make now.
Exploring parallel sectors and meeting people and companies who have already made the shift from technical product to commercial business.
Outcomes: a fresh perspective and contacts outside medtech who've already made this leap.
Stress-test your strategy against the futures that could actually happen (faster uptake, a slower regulatory path, a competitor moving first), working through it with peers reading the same market signals.
Outcomes: a set of scenarios and risks that go straight into your own planning.
Creating commitments to yourself, your team and your cohort to build on and maintain the energy generated through the Studio.
Outcomes: more than a plan, a support network to hold your accountability for growth.
What “beyond the device” looks like in practice.
Four patterns from Xenergie's European MedTech market research: the kind of live, organisation-wide question this Studio is built to work on.
“A CE-marked diagnostics business, live in the health system since last year, raised eight figures this summer to fund European and US expansion. The question: how does a single diagnostic product become a scalable platform?”
“A device-plus-service business already used in care pathways is weighing whether its next stage of growth comes from broader adoption, or from the data it's now generating at scale.”
“A regulated surgical technology company selling into 20+ countries is working out whether its growth engine should be procedure adoption, recurring consumables, or licensing, and whether its organisation is built for all three at once.”
“A medical device company has become a consumer wearables business almost by accident, and the two now pull in different directions. Investors are pricing it on how fast it scales, but the leadership team was built for research, not for commercial pace.”
Illustrative patterns drawn from Xenergie's European MedTech market research. Not confirmed participants.
Candour is engineered, not hoped for.
The conditions below are constant across every Studio, whatever the sector.
No direct competitor in, or likely to join, the same cohort. Candour depends on it.
Confidentiality, conduct and no solicitation, agreed in week one with stated consequences.
Enforced by the facilitator throughout, and briefed to every visiting expert.
Fit and willingness to share are tested in conversation, never assumed from a job title.
Where the work continues, supported by digital tools and coaching, not left to drift.
Small enough that everyone is exposed, large enough that the room holds real range.
What CEOs ask us before they join.
No. A peer forum builds trust but rarely has a diagnostic method underneath it; an accelerator or faculty programme teaches well but leaves the translation back into your organisation to you. A Studio is both at once, applied to your own live question.
Six sessions from January to June 2027, two of them in-person anchor days. Before that, a short webinar in October and a founding cohort half-day in November set the group up to hit the ground running. Between sessions, the work happens inside your own organisation, at a pace you set, supported rather than policed.
No. Non-competing membership is a condition of every cohort, checked before anyone is confirmed, not left to chance.
From €8,000 per seat, or €13,000 for two places from the same organisation. We'll confirm the detail on the call once we understand your situation and cohort composition.
Seven to nine other CEOs and senior leaders from non-competing, commercial-stage European MedTech businesses, curated by Xenergie for genuine range and comparable stage, never disclosed before you've had your own intake call.
Commitments and measures are locked in publicly at session six. Many cohorts choose to keep meeting informally: that's their choice to make, not something Xenergie sells you into.
Irish MedTech cohort: confirm your place before 24 November 2026.
Eight to ten places, one sector, one cohort. A short webinar in October, the founding cohort's first half-day together in November, then the full six-month programme from January 2027. If the question of what your business becomes next deserves that kind of focus, the next step is a conversation about whether this is the room for it.
Or contact Nigel Russell directly · nigel.russell@xenergie.com